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TGFb1 is a regulatory cytokine with a crucial function in the control of T cell tolerance to tumors. Our recent study
revealed that T cell-produced TGFb1 is essential for inhibiting cytotoxic T cell responses to tumors. However, the exact
TGFb1-producing T cell subset required for tumor immune evasion remains unknown. Here we showed that deletion of
TGFb1 from CD8
+ T cells or Foxp3
+ regulatory T (Treg) cells did not protect mice against transplanted tumors. However,
absence of TGFb1 produced by activated CD4
+ T cells and Treg cells inhibited tumor growth, and protected mice from
spontaneous prostate cancer. These findings suggest that TGFb1 produced by activated CD4
+ T cells is a necessary
requirement for tumor evasion from immunosurveillance.
Introduction
In immunocompetent hosts, the adaptive immune system is
postulated to respond to and suppress spontaneous tumor
development.
1,2 In mice and humans, studies have demonstrated
that tumor development induces adaptive immune responses.
3-7
Deficiency in Rag-1, a gene required for the development of T, B
and natural killer T cells, or antibody depletion of CD4
+ or CD8
+
T cells renders mice more susceptible to spontaneous and
carcinogen-induced tumors.
8,9 In addition, tumors that grow on
immunodeficient Rag2
2/2 background are rejected upon trans-
plant into immune-intact mice whereas transplant of tumors from
wild type mice into wild type mice does not result in tumor
rejection.
8-10 These findings demonstrate a host-protective role for
lymphocytes in tumor development and further show that
lymphocytes can also shape the immunogenicity of tumors.
The effector mechanisms that trigger lymphocyte-dependent
defense against cancer have begun to be understood. Heterozygo-
sity for the tumor suppressor Trp53 predisposes hosts to tumor
development. Trp53
+/2 mice that are simultaneously deficient in
perforin, the pore-forming molecule required for the cytolytic
function of CD8
+ T and NK cells spontaneously develop B cell
lymphomas with an earlier onset than Trp53
+/2 mice.
11
Lymphomas arising in these mice are rejected by a CD8
+ T
cell-dependent mechanism upon transfer into wild type mice but
grow progressively in perforin-deficient recipients.
11 These find-
ings indicate a requirement for cytotoxic CD8
+ T cell function for
tumor rejection and the shaping of tumor cell immunogenicity.
IFNc is an effector cytokine produced predominantly by activated
lymphocytes. Treatment of wild type mice with IFNc neutraliza-
tion antibodies results in tumor outgrowth.
8 Additionally,
abrogation of IFNc signaling either by IFNc or IFNGR1
deficiency results in spontaneous disseminated lymphomas and
increased sensitivity to MCA-induced sarcomas.
9,12 Although the
specific cell type-produced IFNc that is required for tumor
surveillance remains undefined, these findings demonstrate that
IFNc sensitivity is essential for tumor rejection.
Cancer development is a complex process and the functional
outcomes of tumor recognition by T cells differ between tumor
types. In a transgenic model of spontaneous cancer where the
simian virus 40 T antigen (SV40 Tag) oncogene triggers tumor
development in diverse tissues, tumors induce Tag-specific CD8
+ T
cell responses but these T cells are unable to kill target cells.
7 In
addition, in the transgenic adenocarcinoma of mouse prostrate
(TRAMP) model of cancer, a high proportion of cells that infiltrate
prostate tumors are T cells.
13 However, tumor burden in TRAMP
mice deficient in adaptive immunity are not affected compared
with control TRAMP littermates,
13 suggesting functional defects or
intrinsic inability of adaptive immunity-mediated TRAMP tumor
immunosurveillance. TRAMP tumorsexpress a histoneH4 peptide
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self antigen that is recognized by CD8
+ T cells.
5 When naïve
tumor-reactive TCR transgenic (HRC) T cells are transferred into
TRAMP mice, the T cells recognize the histone H4 peptide but
show limited effector functions.
5 Thus, T cell-mediated tumor
rejection is not observed in these tumor models. Instead, tumor
growth is associated with the functional defects in tumor antigen-
specific T cells. Such a phenomenon of T cell tolerance is not
restrictedto animal models. In melanoma patients, tumor-specific T
cell responses can arise de novo, but similar to animal models, these
T cells have blunted responses to tumor antigens.
3,4 These
observations imply that T cell dysfunction is likely a general
phenomenon found in spontaneous tumors.
How autochthonous tumors induce T cell tolerance is of
interest not only for understanding disease mechanisms but also
for cancer immunotherapy. One prominent factor that is often
overproduced in animal models of cancer and cancer patients is
transforming growth factor   (TGF ). TGF  is a family of
regulatory cytokines comprising TGF 1, 2 and 3. The TGF 
ligands elicit their biological activity by binding the serine or
threonine kinases TGF  type I (TGF RI) and type II (TGF RII)
receptors leading to the phosphorylation and activation of Smad2
and Smad3 transcription factors and subsequent regulation of
Smad-dependent genes.
14 Among the three isoforms of TGF ,
TGF 1 is the most highly expressed in the immune system.
Tgfb1-null mice manifest severe autoimmune multiorgan patho-
logy that includes lymphadenopathy and myocarditis and die
around three to four weeks of age.
15,16 Because TGF 1 regulates
the homeostasis of both lymphoid and non-lymphoid tissues, the
contribution of T cells to the pathological phenotype of mice
harboring germline deletion of the Tgfb1 gene had to be
definitively determined. On a genetic background of either
MHC class I or class II deficiency, the inflammatory phenotype
and severe wasting disease that characterize TGF- -null mice are
greatly ameliorated indicating that disease pathology in these mice
is mediated mainly by CD4
+ and CD8
+ T cells.
17,18 In other
studies to address the role of TGF  signaling in T cell tolerance,
mice with T cell-specific deletion of TGF-RII alleles were
generated.
19,20 In these studies, it was shown that abrogation of
TGF  signaling in T cells phenocopies Tgfb1-null mice.
19,20
These findings indicate that TGF  signaling plays a crucial role in
the maintenance of peripheral T cell tolerance to self-antigens.
Whether TGF  suppresses T cell surveillance for malignancy is
not completely addressed. In tumor transplantation studies,
inhibition of TGF  signaling in T cells either by expression of a
dominant negative mutant of TGF RII (DNR), or the administra-
tion of blocking antibodies or soluble TGF RII improve T cell
responses and inhibits tumor growth.
21-26 However these studies fail
to recapitulate the physiological function of TGF  in T cell
responses to autochthonous tumors. In a model of cancer where
SV40 Tag oncogene induces sporadic tumor development in diverse
tissues, studies by Willimsky and Blankenstein showed that tumor
growth results in general CTL unresponsiveness. Importantly, CTL
dysfunction is also associated with elevated serum concentration of
TGF 1 cytokine.
7 These findings corroborate studies in cancer
patients where increased TGF  production is a negative prognostic
indicator.
21 Altogether, these results reveal that elevated production
of TGF 1 occurs in animal models and human cancers and is
associated with T cell unresponsiveness.
However, it remains unknown whether TGF  production is a
consequence or a direct cause of T cell functional defects in
tumor-bearing hosts. Recently, we have used TRAMP mice with
T cell-specific attenuation of TGF  signaling via transgenic
expression of dominant negative form of TGF RII (DNR) to show
thatblockadeofTGF signalinginDNR-TRAMPmiceresultsinT
cell differentiation into IFNc and GzmB-producing effectors that
suppressed tumor development in TRAMP mice.
13 In addition, in
cases where the tumors did grow, they did not advance to higher
histological grades in DNR-TRAMP mice. In adoptive transfer
experiments, HRC CD8
+ T cells that are specific to histone H4
peptide self-antigen, expressed by TRAMP tumors, are bereft of
antitumor activity reflecting tolerance.
5 When we crossed HRC
mice to DNR mice, we found that DNR-HRC CD8
+ Tc e l l sa r e
resistant to tolerance induction upon transfer into TRAMP mice as
measured by proliferation and GzmB expression in the draining
lymph nodes and prostate.
13 These observations indicate that TGF 
signaling regulates tumor antigen-specific T cell proliferation
and GzmB expression and further suggest that TGF  production
is likely not a consequence but rather a direct cause of T cell
unresponsiveness in tumor-bearing hosts.
Virtually all nucleated cells produce TGF , and because of the
ubiquitous expression of the TGF  receptors, almost every cell
type responds to TGF . As a result, which cell type-produced
TGF  mediates the suppression of T cell response to tumors is an
important question. One of the earliest indications of the role of
TGF  in tumor development was demonstrated in the early
1990s by overexpression of an active form of TGF 1 in a highly
immunogenic tumor cell line. This modified cell line, but not the
parental line, suppressed anti-tumor immune responses.
27 This
finding formed the basis of the classical notion that tumor cell-
produced TGF  inhibits T cell responses and promotes immune
evasion. However, a critical evaluation of data from these studies
would argue that they simply indicate that over-production of
active TGF  in tumors can cause T cell hyporesponsiveness
without pointing out the precise source of the TGF  under
physiological settings. Thomas and Massague addressed this
question more definitively using RNA interference to knock down
EL4 tumor-derived TGF 1.
25 When analyzed for tumor
immunity, this modified EL-4 tumor did not induce protective
antitumor T cell responses whereas tumor expression of soluble
TGF RII enhanced T cell responses, suggesting that TGF 1
derived from host but not tumor cells might be more important
for T cell functional defects.
Understanding the precise source of TGF 1 that induces T cell
dysfunction to tumors is of fundamental interest as it could
facilitate the development of more targeted cancer therapies.
Earlier, we showed that TGF 1 produced by T cells controls T cell
differentiation and tolerance in autoimmunity settings.
28 More
recently, we also we demonstrated an important function for T
cell-produced TGF 1 in the control of T cell responses to
autochthonous tumors and metastasis.
13 We found that deletion of
T cell TGF 1 in TRAMP mice resulted in the differentiation of
CD4
+ and CD8
+ T cells into IFNc and GzmB-producing effectors
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in the draining lymph nodes and prostate, and inhibited tumor
development in TRAMP mice.
13 In metastasis assay, deficiency of
TGF 1 in T cells also prevented lung colonization by B16-OVA
tumors. Additionally, chromium release assays revealed that tumor-
specific CTL response was specifically mediated by CD8
+ T cells in
Tgfb1
f/n Cd4-cre mice. Altogether, these findings show that T cell
tolerance to tumors is controlled by T cell-produced TGF 1
independent of tumor-derived TGF 1. However, which precise
subpopulation of T cells produce TGF 1 to suppress T cell
responses to tumors remains to be determined.
In this study, we crossed mice carrying floxed/null alleles of
Tgfb1 to a series of cre recombinase strains of mice to further
delineate the function of TGF 1 produced by specific sub-
population of T cells in tumor development. We found that
deletion of TGF 1 from either CD8
+ T cells or Foxp3
+ regulatory
T cells alone did not suppress lung colonization by B16-OVA
tumors. However, deficiency of TGF 1 from activated CD4
+ T
cells and Treg cells inhibited tumor development in TRAMP
mice and protected mice from lung colonization by B16-OVA
tumors. These results suggest that TGF 1 production by activated
CD4
+ T cells is necessary for inhibiting T cell surveillance of
tumors.
Results
TGF 1 produced by Treg cells and CD8
+ T cells is dispensable
for the immune tolerance of B16-OVA tumors. TGF 1
produced by T cells has comprehensive effects in tumor develop-
ment: it suppresses antitumor T cell function to promote
both primary tumor growth and tumor metastasis. However, in
Tgfb1
f/n Cd4cre mice, the Tgfb1 gene is deleted from all T cells.
Thus the precise TGF 1-producing T cell subpopulation
required for the control of tumor immune tolerance remains
unknown. To address this question, we employed T cell
subpopulation-specific TGF 1-deficient strains of mice. In an
earlier study, we demonstrated that deletion of TGF 1 from
CD4
+Foxp3
+ regulatory T cells was insufficient to inhibit primary
tumor growth in Tgfb1
f/n Foxp3cre-TRAMP mice.
13 In addition,
Treg cell-produced TGF 1 is dispensable for suppressing the
differentiation of effector T cells in TRAMP tumors.
13 In this
report, we tested the function of Treg cell-derived TGF 1i n
tumor metastasis. We found that lung colonization by B16-OVA
tumors was comparable between Tgfb1
f/n Foxp3-cre mice and
Tgfb1
f/n control littermates (Fig.1A and B). This finding
established that production of TGF 1 by Treg cells is not
Figure1. Treg cell- or CD8
+ T cell-derived TGFb1 is dispensable for promoting tumor growth (A and B) B16-OVA melanoma cells were injected into age-
matched Tgfb1
f/n and Tgfb1
f/n Foxp3-cre mice and pulmonary metastatic nodules assessed 15– 21 days later. (C) RT-PCR showing the deletion of Tgfb1
gene from FACS-sorted CD4
+ and CD8
+ T cells isolated from Tgfb1
f/n Cd8-cre mice and Tgfb1
f/n control littermates (D and E) B16-OVA melanoma cells were
injected into age-matched Tgfb1
f/n and Tgfb1
f/n Cd8-cre mice and pulmonary metastatic nodules assessed 15–21 days later.
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essential for the induction of host tolerance to primary TRAMP
tumors as well as B16-OVA tumors.
To investigate the effects of CD8
+ T cell-produced TGF 1o n
tumor immune tolerance, we generated Tgfb1
f/n Cd8cre mice
by crossing Tgfb1
f/n mice with Cd8-cre transgenic mice. Using
RT-PCR, we confirmed that the Tgfb1 gene is efficiently deleted
specifically from CD8
+ T cells (Fig.1C). Interestingly, B16-OVA
tumor lung colonization was comparable between Tgfb1
f/n Cd8cre
mice and Tgfb1
f/n littermate controls (Fig.1D and E). In tumor-
specific chromium release assays, deficiency of CD8
+ T cell-
derived TGF 1 did not improve the ability of splenocytes to kill
EL-4 target cells compared with splenocytes from wild type mice
(data not shown). These observations reveal a nonessential role for
CD8
+ T cell-derived TGF- 1 in suppressing B16-OVA tumor
lung colonization and EL-4 tumor-specific cytolytic activity.
Deletion of TGF- 1 from activated CD4
+ T cells and Treg
cells inhibits tumor development. To further narrow down
the cellular source of TGF 1 in tumor immune tolerance, we
generated Tgfb1
f/n Tnfrsf4 (encoding Ox40)-cre mice by crossing
Tgfb1
f/n mice with Tnfrsf4-cre transgenic mice. We showed
recently that Tnfrsf4-cre induces efficient deletion of the Tgfb1
allele in Treg cells and activated CD4
+ T cells with minimal
deletion in naïve T cells and activated CD8
+ T cells.
29 When
tested for the effect of TGF 1 deficiency in activated CD4
+ T and
Treg cells, we found that Tgfb1
f/n Tnfrsf4-cre mice were protected
from B16-OVA lung colonization compared with Tgfb1
f/n control
mice (Fig.2A and B). Occasionally, tumor nodules were found
growing in other organs such as the kidney and the peritoneal
cavity. Therefore, we reasoned that lung colonization per se would
not be a definitive measure of host protective immunity. When
assessed for survival, whereas Tgfb1
f/n mice (n = 5) had an average
survival of 35 days, one Tgfb1
f/n Tnfrsf4-cre mouse lived beyond
56 days, and was sacrificed without any obvious signs of disease.
The remaining four Tgfb1
f/n Tnfrsf4-cre mice had an average
survival of 41 d (data not shown). Because we observed compar-
able tumor burden between Treg cell-specific TGF- 1-deficient
mice and their control littermates(Fig.1A and B), these findings
imply that TGF 1 produced by activated CD4
+ T cells is essential
for promoting B16-OVA tumor growth.
Given that B16 tumors secrete TGF 1,
30 protection against B16-
OVA lung colonization in Tgfb1
f/n Tnfrsf4-cre mice suggests that
absence of TGF 1 from activated CD4
+ T cells and Treg cells is
sufficient for generation and maintenance of antitumor immunity
independent of tumor-derived TGF 1. To further test this
hypothesis and also determine if the inhibitory function of
TGF 1 from activated CD4
+ T cells is applicable to other tumor
types, we utilized EL-4 thymoma, another tumor that secretes
TGF 1.
22 We injected the mice intraperitoneally and ten days later,
assessed EL-4 tumor-specific cytolytic activity ina chromium release
assay. We found that splenocytes from Tgfb1
f/n-Tnfrscre mice
showed significantly higher EL-4-specific cytolytic activity than
splenocytes from Tgfb1
f/n mice (Fig.2C). This observation strongly
implies that TGF 1 produced by activated CD4
+ T and Treg cells
suppresses the generation of tumor-specific T cell effector activity.
Transplanted tumor-induced immune responses could be
fundamentally different from those of spontaneous tumors.
31
Thus we needed to further substantiate, in a more physiological
way, the acquisition of antitumor immunity due to the absence of
TGF 1 derived from activated CD4
+ T cells and Treg cells. To this
end, we bred Tgfb1
f/n Tnfrsf4-cre mice to TRAMP mice to obtain
Tgfb1
f/n Tnfrsf4cre-TRAMP mice. When evaluated at 8 mo of age,
Tgfb1
f/n Tnfrsf4cre-TRAMP mice had substantially lower tumor
burden than Tgfb1
f/n-TRAMP mice (Fig.3A). Analogous to
Figure2. Deficiency of TGFb1 in activated CD4
+ T cells and Treg cells
enhances tumor-specific CTL responses (A and B) B16-OVA melanoma
cells were injected into age-matched Tgfb1
f/n and Tgfb1
f/n Tnfrsf4-cre
mice and pulmonary metastatic nodules assessed 15–21 days later.
The p value between two groups of pulmonary metastatic nodules is
shown (Students t-test) *Depicts statistically significant difference.
(C) Tgfb1
f/n and Tgfb1
f/n Tnfrsf4-cre mice were challenged intraperitone-
ally with 1   10
6 El-4 tumor cells and the splenocytes were used as
effectors against EL-4 targets at the indicated effector:target ratios.
Chromium-51 (Cr-51) release assay 10 days after tumor challenge is
shown. The p values between the two groups of number of metastatic
nodules and percent Chromium-15 release are shown (Students t-test).
*Depicts statistically significant difference.
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TRAMP mice with attenuated T cell TGF-  signaling and total T
cell-specific deletion of TGF 1,
13 CD4
+ and CD8
+ Tc e l l si nTgfb1
f/
n Tnfrsf4cre-TRAMP mice differentiated into producers of IFNc in
the tumor-draining lymph nodes (Fig.3B). Compared with the
tumor draining lymph nodes, the CD8
+ T cells that migrated into
the prostates further upregulated GzmB production in Tgfb1
f/n
Tnfrsf4cre-TRAMP mice compared with Tgfb1
f/n-TRAMP controls
(Fig.3B). Because Tgfb1
f/n Foxp3cre-TRAMP mice are not
protected from tumor development,
13 these findings suggest that
the inhibition of T cell responses in TRAMP mice has a specific
requirement for TGF 1 produced by activated CD4
+ T cells.
The functional outcome of T cell responses to tumors depends
on the integration and balance of antitumor responses and
inhibitory signals. The expression of programmed death 1 (PD-1)
onactivatedTcellslimitseffectorT-cellresponses.PD-1expression
on tumor infiltrating T cells plays an important role in the
induction and maintenance of T-cell unresponsiveness in
tumors.
32,33 In our recent report, we found that blockade of
TGF  signaling in T cells or deletion of TGF 1 from T cells in
TRAMP mice led to diminished PD-1 expression in tumor-
infiltrating CD8
+ T cells compared with CD8
+ T cells from control
Tgfb1
f/n-TRAMP littermates.
13 Consistent with this observation,
analysis of Tgfb1
f/nTnfrsf4cre-TRAMP mice showed that protection
against tumor development was associated with reduced PD-1
expression in tumor-infiltrating CD8
+ T cells (Fig.3B). Altogether,
these findings suggest that augmented anti-tumor immunity
in Tgfb1
f/n Tnfrsf4cre-TRAMP mice is associated with increase in
cytotoxic molecule expression with concomitant reduction in
immunoinhibitory signals in tumor-infiltrating CD8
+T cells.
Discussion
Although T cell unresponsiveness in nonvirus-induced tumors is a
well-known phenomenon, the underlying mechanisms remain
Figure3. Deficiency of TGF-b1 in activated CD4
+ T cells and Treg cells inhibits tumor development (A) Tgfb1
f/n-TRAMP and Tgfb1
f/n Tnfrsf4-cre-TRAMP
mice were evaluated for tumor development at 8 months of age. The weights (Wt) of urogenital tracts (UG) normalized to body Wt ± s.e.m of Tgfb1
f/n
TRAMP (n = 4) and Tgfb1
f/n Tnfrsf4-cre TRAMP (n = 3) mice are shown. The p value between two groups of tumor burden is shown (Students t-test).
*Depicts statistically significant difference. (B) Flow cytometric analysis examining the expression of interferon gamma (IFNc), granzyme B (GzmB) and
PD-1 proteins in CD4
+ and CD8
+ T cells in the draining lymph nodes and prostates of Tgfb1
f/n TRAMP and Tgfb1
f/n Tnfrsf4cre-TRAMP mice. For IFNc
expression, T cells were re-stimulated in vitro for five hours with phorbol 12-myristate 13-acetate (PMA), ionomycin and GolgiStop. Representatives of
two independent experiments are shown.
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poorly understood. Production of TGF 1 cytokine is commonly
associated with T cell dysfunction and tumor progression in
cancer patients and experimental models of cancer. We showed
recently using a model of oncogene-induced prostate cancer that
T cell-specific attenuation of TGF  signaling resulted in T cell
differentiation into potent effectors that blocked tumor develop-
ment, suggesting that cell-intrinsic TGF  signaling mediates
T cell tolerance and promotes the development of oncogene-
induced tumors.
13 Additionally, we demonstrated that T cells
themselves are the major in vivo source of TGF 1 cytokine that
suppresses the capacity of T cells to survey for malignancy.
13 Here
in this study, we have further demonstrated that deletion of
TGF 1 from activated CD4
+ T cells and Treg cells but not
CD8
+ T cells or Treg cells alone protected mice from tumor
development. This finding established a specific requirement for
TGF 1 from activated CD4
+ T cells and provided insight into
the mechanism of tolerance mediated by TGF  in tumor
development.
T cell tolerance could occur anywhere between the tumor-
draining lymph nodes, where naïve tumor-specific T cells are
primed, and the tumor sites after T cell infiltration. In the current
view, TGF  is thought to exert its suppressive effects on T cells at
the effector phase. Once at the tumor site, T cells experience large
quantities of TGF  secreted by tumors that render T cells
ineffective at killing target cells. This notion has held sway partly
because it is an appealing model although direct evidence for it
is lacking. In our recent findings, we provided an alternative
mechanistic insight into TGF -mediated negative regulation of
T cell responses to tumors (Fig.4). We showed that tumor
development triggered substantially higher phosphorylation
Figure4. Model of TGFb-mediated inhibition of antitumor T cell response. In the tumor-draining lymph nodes, CD4
+ T cells become activated in
response to tumor-associated antigens. Activated CD4
+ T cells in the tumor draining lymph nodes secrete TGFb1 that suppresses the activation,
proliferation and differentiation of naïve tumor-specific CD8
+ T cells into IFNc-secreting T cells. Consequently, activated CD8
+ T cells that migrate to
the tumor site as effectors fail to elaborate CTL functions including GzmB expression. In addition, effector CD4
+ T cells at the tumor site might also
produce TGFb1 to suppress the effector activities of CD8
+ T cells. The net result is CTL dysfunction, which allows tumors to grow.
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of Smad2 and Smad3 in the tumor draining lymph nodes of
8-mo-old TRAMP mice than in other tissues including the
tumor.
13 This was an intriguing finding and it revealed that higher
T cell TGF  signaling is coincident with T cell priming to tumor
antigens. By attenuating T cell intrinsic TGF  signaling using
DNR-TRAMP mice and deleting T cell TGF- 1 using Tgfb1
f/n
Cd4cre-TRAMP (TKO-TRAMP) mice, we inhibited T cell Smad
phosphorylation in the tumor-draining lymph nodes resulting in
blockade of tumor development.
13
Because use of Cd4 promoter to delete the Tgfb1 allele in
Tgf 1
f/n Cd4-cre mice results in nonselective loss of TGF 1 from
all T cells in Tgf 1
f/n Cd4cre-TRAMP mice, one crucial question
could not be addressed by this approach, that is the contribution
of TGF 1 produced by specific T cell subpopulations to the
observed inhibitory effect of TGF 1 in T cell antitumor
responses. Because of the pleiotropic function of the TGF 1
cytokine, it is possible that TGF 1 produced by different sub-
populations of T cells could prohibit T cell responses in one
context of immune responses but not another. Distinguishing
between such subtleties in TGF 1 function is important for
understanding the TGF -mediated mechanism of immune
regulation. Indeed, when we crossed Tgf 1
f/n mice to different
Cre recombinase strains of mice, we found that lung colonization
by B16-OVA, a cell line that produces TGF 1,
30 was inhibited in
Tgf 1
f/n Tnfrsf4-cre mice but not Tgf 1
f/n Cd8-cre or Tgf 1
f/n
Foxp3-cre mice. Additionally, when tested for protective tumor
immunity against EL-4, another tumor that produces substantial
amounts of TGF 1,
22 absence of TGF 1 in activated CD4
+
T cells and Treg cells but not CD8
+ or Foxp3
+ Treg cells alone
resulted in the induction of high tumor-specific cytolytic activity.
Altogether, these findings suggest that TGF 1 produced by
activated CD4
+ T cells is required for negative regulation
of tumor-specific CTL responses in these transplanted tumor
models (Fig.4).
To investigate whether TGF 1 produced by activated CD4
+ T
cells regulates T cell responses to spontaneous tumors, we
generated Tgfb1
f/n Tnfrs4cre-TRAMP mice by crossing TRAMP
mice to Tgfb1
f/n Tnfrs4-cre mice. Similar to DNR-TRAMP and
Tgfb1
f/n Cd4cre-TRAMP mice, we found that Tgfb1
f/n Tnfrs4cre-
TRAMP mice were protected from tumor development compared
with control Tgfb1
f/n-TRAMP littermates. This observation
suggests that TGF 1 produced by activated CD4
+ T cells
promotes TRAMP tumor development. Because tumorigenesis
is driven by the same rat probasin promoter activity, it is
reasonable to assume equivalent SV40 Tag-induced transforma-
tion and tumor initiation events between control Tgfb1
f/n-
TRAMP and Tgfb1
f/n Tnfrs4cre-TRAMP mice. Therefore, this
difference in tumor burden that we observed is likely to be direct
consequences of immune intervention via the deficiency of
TGF 1 from activated CD4
+ T cells. Indeed, protective tumor
immunity was associated with enhanced GzmB and IFNc
expression in the tumor-draining lymph nodes and prostate of
Tgfb1
f/n Tnfrs4cre-TRAMP mice and enhanced EL-4 tumor-
specific cytolytic activity in Tgfb1
f/n Tnfrs4-cre mice. In our recent
findings, we showed that although the T cells in wild type
TRAMP mice that trafficked to tumor tissue had significantly
dissipated TGF -induced Smad phosphorylation, CD8
+ T cells
failed to elaborate GzmB.
13 TGF  has been shown to directly
inhibit GzmB transcription in a Smad-dependent manner.
25 It is
possible that TGF  regulates GzmB expression through Smad-
independent pathways in tumors. Alternatively, low GzmB
expression in CD8
+ T cells in the tumor might be a long-lasting
footprint of T cell TGF  signaling in the tumor draining
lymph nodes.
Our findings contradict earlier work by several groups showing
that tumor-produced TGF  promotes tumor escape from
immune surveillance.
23,27,34,35 One possible explanation for these
different findings is that mechanisms of TGF -mediated T cell
tolerance differ between primary tumors and the transplanted
tumor models used in the aforementioned studies. Because of the
broad distribution of the TGF  receptors,
36 tumor cells and other
cells in the immediate vicinity of the tumor will most likely
consume TGF  secreted by tumors before it reaches the draining
lymph nodes to regulate T cell differentiation. Thus, tumor-
derived TGF 1 probably makes only a minor contribution to
the observed TGF -mediated T cell tolerance. Nonetheless, a
definitive function of tumor cell-produced TGF 1 in control of
tumor immunosurveillance would require the generation of tumor
cell-specific TGF 1-deficient mice.
Immune response to tumors is a complex battlefield with both
tumor-suppressing and tumor-promoting pathways vying for
dominance. The integration and balance of these signals
ultimately determines the outcome of tumor immune recognition.
Expression of the inhibitory co-receptor PD-1 in activated CD8
+
T cells has been linked with the induction and maintenance of
T-cell dysfunction in tumors.
32,33,36-39 In TRAMP mice with
deletion of TGF 1 from activated CD4
+ T cells, host-protective
immunity was associated with diminished PD-1 expression in
tumor-infiltrating CD8
+ T cells. This observation is consistent
with PD-1 expression on CD8
+ T cells that infiltrate the prostates
of DNR-TRAMP and Tgfb1
f/n Cd4cre-TRAMP mice that we
reported recently.
13 TGF  might directly promote PD-1
expression in tumor-infiltrating T cells. In melanoma patients,
defective tumor-specific CD8
+ T cell responses occur in response
to chronic antigen stimulation in association with the induction of
PD-1 expression.
32 Thus, there remains the possibility that the
reduced PD-1 expression in CD8
+ T cells is secondary to the
tumor protection. The exact mechanism by which TGF 
regulates PD-1 expression, and the molecular targets downstream
of TGF  that antagonize antitumor T cell activity are open for
future investigation.
TGF 1 is secreted as an inactive form that needs to be liberated
from the constraints of the latency-associated protein.
40 Among
other mechanisms, dendritic cell-expressed av 8 integrin is
required for the activation of latent TGF 1 and for the regulation
of T cell responses.
41,42 Therefore, the selectively enhanced TGF 
signaling in tumor-draining lymph node T cells reported in our
recent studies
13 may be due to the specific requirement of
dendritic cells to prime naïve T cells. It also remains to be
determined whether the observed requirement of T cell TGF 1
for enhanced Smad phosphorylation in the tumor-draining lymph
node T cells is specifically dependent on TGF 1 from activated
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CD4
+ T cells. At what time point activated CD4
+ T cells secrete
TGF 1 in sufficiently large quantities to regulate CD8
+ T cell
effector activity is unknown. Does T cell tolerance induction
require some threshold of tumor burden to allow high amounts of
tumor-associated antigens to trigger T cell TGF 1 secretion as a
result of chronic antigen stimulation in the tumor-draining lymph
nodes? In a tumor model where tumorigenesis is triggered by
stochastic Tag oncogene activation, Willimsky and Blankenstein
demonstrated that high TGF 1 levels are already present in mice
with premalignant lesions (defined by presence of anti-Tag IgG in
the serum without visible tumors) and this phenomenon is
associated with the induction of CTL unresponsiveness.
43 This
observation underscores increased TGF 1 levels in tumor-bearing
hosts as an early event. In that study, no evidence was found
linking high TGF 1 levels to tumor cells. Thus, it is likely that
T cell secretion of TGF 1 to inhibit T cell tumor immunity is a
very early event that starts when the T cells first encounter tumor-
associated antigens.
The emerging insights from our study provide basis for a more
informed understanding of the role of TGF  in suppressing
adaptive immune control of cancer. Blockade of TGF -dependent
immune suppression represents a clinically relevant approach for
cancer therapy. Indeed, various strategies to modulate TGF 
signaling are already in different stages of clinical evaluation
including neutralizing antibodies (Genzyme, GC-1008), silencing
oligonucleotides (Antisense Pharma, AP12009) and small mole-
cule inhibitors (Lilly Research Laboratories, LY364947).
However, owing to the pleiotropic properties of TGF , important
caveats relating to both safety and efficacy of TGF  modulators
raise reasonable concerns. TGF  has a dual function in tumor
development; not only does it promote cancer progression but it
can also suppress tumor development posing a great challenge to
the development of TGF -targeted cancer therapies. In fact, the
contribution of the anti-proliferative effect of TGF  to suppres-
sing tumor growth has recently been documented in animal
models of spontaneous cancer. When prostate epithelial cells were
specifically attenuated for TGF  signaling via transgenic
expression of dominant negative TGF RII, TRAMP tumor
growth was accelerated compared with wild type controls.
44 The
goal of TGF -targeted therapy is to abolish the tumor-promoting
effect of TGF  and preserve its tumor suppressor function
simultaneously. Thus, the therapeutic success of TGF  antagon-
ism will require a better understanding of the mechanisms by
which TGF  promotes tumor development. TGF  blocking
strategies via neutralizing antibodies, small molecule inhibitors
and silencing oligonucleotides lack specificity and consequently
target TGF  signaling systemically without preserving the benefits
of its cytostatic effects on tumor cells. The data discussed here
reveal previously unrecognized cellular mechanism of TGF -
mediated immunosuppression that should affect and inspire the
design of specific TGF -targeting therapies for cancer. Our study
provides rationale for design strategies that block the paracrine
TGF  signaling pathway specifically in T cells. This approach will
not only awaken anti-tumor immunity but will also ensure the
preservation of the cytostatic effect of TGF  on tumor cells for
cancer eradication.
Materials and Methods
Mice. TRAMP, Foxp3-cre, Tnfrsf4-cre mice, and mice with
floxed and null alleles (f/n) of Tgfb1 gene have previously been
described.
28,29,45 Cd8-Cre mice were obtained from the Jackson
Laboratory. Tgfb1
f/n Tnfrsf4-cre TRAMP mice were produced by
crossing Tgfb1
f/n Tnfrsf4-cre mice to wild-type TRAMP mice. All
mice were maintained under specific pathogen-free conditions,
and animal experimentation was conducted in accordance with
institutional guidelines.
Tumor cell lines and injections. Ovalbumin-expressing B16
melanoma cells and EL-4 cells were cultured in vitro in DMEM
and RPMI-1640 media respectively supplemented with 10% fetal
calf serum, 0.1 mM glutamine and 10 U/ml penicillin. B16
melanoma tumor cells were collected by incubation in 0.25%
trypsin. Tumor cells were washed two times in endotoxin-free
PBS, and 1.0   10
5 or 1.0   10
6 cells injected via tail vein (B16)
or intraperitoneally (EL-4) respectively in a volume of 0.2ml PBS.
Cell viability was at least 90% as determined by trypan blue
exclusion.
Isolation of tumor-infiltrating lymphocytes. Tumor tissues
from sacrificed mice were prepared by mechanical disruption
followed by 1 h treatment with 0.5 mg/ml collagenase Type D at
37°C in a shaker. Digested tissues were mashed between glass
slides, layered on a percoll gradient and centrifuged at 3000 rpm
for 30 min. The separated tumor-infiltrating lymphocyte (TIL)
fraction was washed two times in PBS before use.
Flow cytometry. Fluorescently labeled antibodies against CD4,
CD8, TCR- , CD45, GzmB, PD-1 and IFNc markers were
purchased from eBiosciences. Splenocytes and lymph node cells
were depleted of erythrocytes by hypotonic lysis. Splenocytes,
lymph node cells and TILs were incubated with specific
antibodies for 20 min on ice in the presence of 2.4G2 mAb to
block FcgR binding. IFNc and GzmB staining were performed
with the nuclear protein or the intracellular cytokine staining kits
from eBiosciences and BD Biosciences. For intracellular cytokine
staining, cells were stimulated with 50 ng/ml phorbol 12-
myristate 13-acetate (Sigma, PMA), 1 mM ionomycin (Sigma)
and GolgiStop (BD Biosciences) for 4–5 h. After stimulation, cells
were stained with cell surface marker antibodies, fixed and
permeabilized with a Cytofix/Cytoperm kit (BD Biosciences). All
samples were acquired using LSR II flow cytometer (Becton
Dickinson) and analyzed with FlowJo software (Tree Star).
Antitumor cytolytic assay. Freshly isolated splenocytes were
depleted of erythrocytes by hypotonic lysis and evaluated for their
anti-EL-4 lytic activity as described.
22 Chromium-51 (Cr-51)-
labeled target EL-4 cells were incubated with effector splenocytes
at different effector:target ratios for 4 h. The release of radioactive
chromium was measured using a g-counter (Perkin Elmer)
and the percentage of specific Cr-51 release was calculated by
the formula: [(CPM
experimental – CPM
spontaneous) / (CPM
maximum –
CPM
spontaneous)]   100%; where CPM
experimental is Cr-51 release by
target cells incubated with effector cells, CPM
spontaneous is Cr-51
release by equivalent number of targets without effector cells,
and CPM
maximum is total Cr-51 release after addition of 2% Triton
X-100 to an equivalent number of target cells.
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Pulmonary nodule enumeration. Dissected lungs from
sacrificed animals were fixed in Bouin’s fixative and the number
of metastases counted with a dissecting microscope.
Statistical analysis.Student’s t-test was usedto calculate statistical
significance for difference in a particular measurement between
groups. The Wilcoxon rank-sum test was used to assess differences
between samples that did not meet the assumptions of norma-
lity. A p value of , 0.05 was considered statistically significant.
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